Daré Bioscience and Avomeen Partner to Advance Women’s Health Programs
Avomeen will offer contract product development laboratory services to support the advancement of Daré’s innovative pipeline of investigational products dedicated to women’s health.
Daré Bioscience, a clinical-stage biopharmaceutical company focused on women’s health, announced on Sept. 1, 2020 that it has signed an agreement with Avomeen, a contract research, development, and manufacturing organization, under which Avomeen will offer contract product development laboratory services to support the advancement of Daré’s pipeline of investigational innovative products dedicated to women’s health.
Under the agreement, Avomeen will serve as Daré’s preferred provider of product development laboratory service for three years, a Daré press release said. In turn, Avomeen will provide operating and oversight teams, a preferred discounted pricing structure, and scientific personnel dedicated to supporting Daré’s development programs.
The companies are currently working on development-stage programs, including Ovaprene, a hormone-free, monthly contraceptive, according to the press release.
“One of the clear goals of this partnership is to leverage Avomeen’s ingenuity and expertise in biopharmaceutical development to support our clinical program initiatives in women’s health,” said Sabrina Martucci Johnson, president and CEO of Daré Bioscience, in the press release. “Avomeen has a proven track record and impressive regulatory accreditations combined with cutting-edge technological capabilities that we believe will enable us to accelerate development activities across our portfolio.Further, we believe that the partnership agreement will result in greater efficiencies and savings in our research and development expenditures.”
“Avomeen is excited about this partnership and is well positioned to augment the existing clinical technical and regulatory competencies at Daré,” added Mark Harvill, CEO of Avomeen, in the press release. “We have been able to apply our novel scientific and technical solutions to Daré’s diverse portfolio, in large part due to the collaborative approach that Daré implements with its development partners like Avomeen.”
Source: Daré
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
